SBI Securities’s Indaptus Therapeutics INDP Stock Holding History

SBI Securities’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$31	Hold	17	–	–	﹤0.01%	3673
2025 Q4	$49	Hold	17	–	–	﹤0.01%	3579
2025 Q3	$49	Sell	17 -139	-89%	-$1K	﹤0.01%	3722
2025 Q2	$1.64K	Sell	156 -1	-0.6%	-$12	﹤0.01%	2470
2025 Q1	$2.42K	Buy	157 +18	+13%	+$415	﹤0.01%	2215
2024 Q4	$3.28K	Buy	+139	New	+$4.41K	﹤0.01%	2089

Other funds holding INDP

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

SBI Securities's INDP Position: Q1 2026 in Review

SBI Securities held its Indaptus Therapeutics (INDP) position steady in Q1 2026 at 17 shares worth $31. The position accounts for ﹤0.01% of the portfolio, ranked #3673.

SBI Securities first reported a position in INDP in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.28K in Q4 2024. 6 funds tracked by Wall St. Rank hold INDP as of Q1 2026.

SBI Securities held 17 shares of Indaptus Therapeutics worth $31 as of Q1 2026.
SBI Securities left its Indaptus Therapeutics share count unchanged in Q1 2026.
Indaptus Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #3673 holding.
SBI Securities first reported a position in Indaptus Therapeutics in Q4 2024 and has held it in 6 quarters since.
SBI Securities's Indaptus Therapeutics position peaked at $3.28K in Q4 2024.
6 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.